SINOVAC BIOTECH LTD. LISTED ON HALTER USX CHINA INDEX

  • Author: SINOVAC BIOTECH CO.,
  • Date: 2005-09-12
  • Source: SINOVAC BIOTECH CO., LTD.
  • Pageview: 19365

BEIJING , January 6, 2004 – Sinovac Biotech Ltd. ("Sinovac") (“the Company”) (AMEX: SVA) is pleased to announce that its securities has been listed on the Halter USX China Index (HXC), the only index in the world devoted exclusively to US-listed securities of companies that derive the majority of their revenues from the People’s Republic of China. Sinovac joins many of ’s largest and most respected companies on this prestigious index.

In addition, the Company has received queries about the recent fluctuation of its shares price.  Sinovac management is unaware of any material change in the affairs of the Company which would account for the recent price fluctuation. Management believes that recent price fluctuations are generally market-related and not related to corporate or business matters of the Company.

About the Halter USX Index

The Index, created by the Halter Financial Group and calculated and distributed by the Amex, is comprised of companies whose common stock is publicly traded in the and the majority of whose business is conducted within the People's Republic of . The Halter USX China Index was created in response to the unique economic opportunities taking place in , as well as the current dynamics in the capital markets. While there is strong demand for Chinese equity, investors still seek and prefer the transparency offered with a listing. For a company to be included in the Halter USX China Index it must conduct a majority of its business in China, maintain an average market cap of over $50 million for the preceding 40 trading days, trade on the NYSE, Amex or NASDAQ and be approved by USX Selection Committee. Investors can buy the Index by investing in an exchange traded fund (ETF), the PowerShares Golden Dragon Halter USX China Portfolio (PEAK, Trade). For more information please visit www.usxchinaindex.com. The following public companies currently comprise the Halter USX China Index:

 

 

Company Name

Symbol

Petrochina Co Ltd Adr

PTR

China Mobile(hong Kong)ads

CHL

Cnooc Ltd Ads

CEO

Unicom Ads

CHU

Petrol & Chem Ads

SNP

Telecom Ads

CHA

Life Insurance Ads

LFC

Semiconductor Mfg Intl Ads

SMI

Shanda Interactive Enter Ads

SNDA

Utstarcom Inc

UTSI

Huaneng Power Intl Ads

HNP

Aluminum Corp of Ads

ACH

Yanzhou Coal Mining Ads

YZC

Netease.com Inc Ads

NTES

Sina Corp

SINA

51Job Inc.

JOBS

Sinopec Shanghai Petrochem Ads

SHI

Tai Electronics

NTE

Brilliance Automotive Ad

CBA

Tom Online Ads

TOMO

Ctrip.com Intl Ads

CTRP

Sohu.com Inc

SOHU

Guangshen Railway Ads

 GSH

Sinopec Beijing Yan Petr'h'ads

BYH

China Southern Airlines'h'ads

ZNH

chinadotcom corp

CHINA

Yuchai Intl

CYD

Eastern Airlines Ads

CEA

Jilin Chemical Ind Ads

JCC

Intac Intl

INTN

KongZhong Corp

KONG

Webzen Inc Ads

WZEN

Automotive Sys

CAAS

Asiainfo Holdings

ASIA

eLong Inc.

LONG

Deswell Industries

DSWL

Finance Online

JRJC

Linktone Ltd Ads

LTON

Asat Holdings Ads

ASTT

Radica Games

RADA

Qiao Xing Universal Tel

XING

Sinovac Biotech Ltd.

SVA

Pacificnet Inc.

PACT

About Sinovac Biotech Ltd.

 

Sinovac Biotech Ltd. specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as hepatitis A and hepatitis B, influenza, “SARS”, and avian flu. Sinovac is one of the leading emerging biotechnology companies in

Sinovac has three vaccines that have completed all three phases of clinical trials – Hepatitis A, Hepatitis A&B combined, and influenza (flu). The Hepatitis A vaccine, Healive™, is currently experiencing strong sales growth in and applications have been filed for its sale in nine other countries to date. Sinovac’s Hepatitis A&B combined vaccine, Bilive™, is expected to receive approval to commence sales in soon and to achieve similar sales growth to Healive™. The flu vaccine completed clinical trials in April 2004 and a New Drug Application has been filed with the SFDA (Chinese FDA). Approval of Sinovac’s flu vaccine is expected in 2005 upon completion of the flu vaccine production line. Since demand for a safe and effective flu vaccine in greatly outstrips supply, sales are expected to escalate rapidly. Furthermore, since individuals are vaccinated against the flu on an annual basis, demand will remain high every year.

 

Sinovac is currently the only company in the world to be conducting clinical trials for a vaccine to prevent SARS.  The Company is also developing a vaccine targeting avian flu in partnership with the China Center of Disease Control (CDC).

For further information please refer to the Company’s filings with the SEC on EDGAR or refer to Sinovac’s website at www.sinovac.com.

If you would like to receive regular updates on Sinovac please send your email request to info@sinovac.com.

Contact: Investor Relations at (888) 888-8312 or 1 604 684-5990 from outside of North America or info@sinovac.com

THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC ' S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR " PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.

Bookmark and Share

Copyright © 2001-2015 Sinovac Biotech Ltd. All Rights Reserved.

Add: No. 39 Shangdi Xi Road, Haidian District, Beijing, P.R.C. 100085 Supported by elongtian